Skip to main content

Rani Therapeutics Holdings Inc

For the period ended Dec 31, 2023. Filed Mar 20, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 20, 2024

RANI$0.57+5.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Stockholders’ Equity

Class A Common Stock · Class B Common Stock
Shares · Amount · Shares · Amount · Additional Paid In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Non-Controlling Interest · Total Stockholders' Equity
Balance at December 31, 202119,712$229,290$3$55,737$—$(8,331)$74,156$121,567
Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC5,3321(5,174)(1)—————
Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC————12,377——(12,377)—
Issuance of warrants———503———503
Issuance of common stock under employee equity plans, net of shares withheld for tax settlement204———(626)———(626)
Issuance of common stock under employee stock purchase plan39———271———271
Issuance of common stock13————————
Forfeiture of restricted stock awards(5)———(7)——(6)(13)
Equity-based compensation————7,587——8,20815,795
Net loss——————(30,588)(32,756)(63,344)
Other comprehensive loss—————(73)—(76)(149)
Balance at December 31, 202225,295$324,116$2$75,842$(73)$(38,919)$37,149$74,004
Issuance of common stock under employee equity plans, net of shares withheld for tax settlement557———(162)———(162)
Issuance of common stock under employee stock purchase plan144———355———355
Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC42————————
Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC————181——(181)—
Forfeiture of restricted stock awards(2)———(6)——(6)(12)
Equity-based compensation————9,552——9,46819,020
Net loss——————(33,970)(33,913)(67,883)
Other comprehensive gain—————61—60121
Balance at December 31, 202326,036$324,116$2$85,762$(12)$(72,889)$12,577$25,443
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.